Web Results
www.nature.com/articles/s41419-021-03475-4

Feb 15, 2021 ... et al. Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci. 98, 1388–1393 (2007).

endpts.com/glaxosmithkline-astrazeneca-butt-heads-over-licensing-rights-to-key-parp-inhibitor-report

GlaxoSmithKline, AstraZeneca butt heads over licensing rights to key PARP inhibitor — report · Biotech Halftime Report: After a bumpy year, is biotech ready to ...

endpts.com/glaxosmithkline-punts-a-key-zejula-combo-study-in-ovarian-cancer-dimming-prospects

Jul 28, 2021 ... A chink has appeared in the armor of data that GlaxoSmithKline R&D chief Hal Barron has been building for the PARP inhibitor Zejula.

www.globenewswire.com/en/news-release/2021/04/12/2208087/0/en/Zentalis-Pharmaceuticals-Enters-into-Clinical-Collaboration-and-Supply-Agreement-with-GlaxoSmithKline-to-Evaluate-its-Oral-WEE1-Inhibitor-ZN-c3-in-Combination-with-Niraparib-a-PARP.html

Apr 12, 2021 ... “This clinical collaboration and supply agreement with GSK allows us to ... PARP inhibitors prevent DNA damage repair in cancer cells.

www.clinicaltrialsarena.com/news/zentalis-gsk-collaboration-agreement

Apr 12, 2021 ... ZEJULA is an FDA and EMA-approved oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor. At present, Zentalis is conducting ...

www.reuters.com/article/us-gsk-approvals-zejula-idUKKBN22B33P

Apr 29, 2020 ... PARP inhibitors work by blocking enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells.

cancerletter.com/drugs-and-targets/20200501_14

May 1, 2020 ... Until now, only 20% of women with ovarian cancer, those with a BRCA mutation, were eligible to be treated with a PARP inhibitor as monotherapy ...

www.precisiononcologynews.com/regulatory-news-fda-approvals/gsk-gets-broad-zejula-indication-ovarian-cancer-fda-deems-myriad

Apr 30, 2020 ... NEW YORK – The US Food and Drug Administration has approved GlaxoSmithKline's PARP inhibitor niraparib (Zejula) as a first-line maintenance ...

www.biopharmadive.com/news/gsk-parp-zejula-first-line-ovarian-astrazeneca-lynparza/558769

Jul 15, 2019 ... Topline results from the Phase 3 PRIMA study show GSK's Zejula, which inhibits a DNA repair enzyme called PARP, significantly improved ...

www.pmlive.com/pharma_news/gsks_zejula_challenges_azmercks_lynparza_in_parp_inhibitor_category_1311434

Sep 30, 2019 ... AstraZeneca/Merck has unveiled new positive data for its PARP inhibitor Lynparza in ovarian cancer – as has its rival from GlaxoSmithKline, ...

www.gsk.com/en-gb/media/press-releases/fda-approves-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-regardless-of-biomarker-status

Apr 29, 2020 ... Niraparib is an oral, once-daily PARP inhibitor that is currently being evaluated in multiple pivotal trials. GSK is building a robust niraparib ...